Haleon/$HLN

1D1W1MYTD1Y5YMAX

About Haleon

Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Ticker
$HLN
Sector
Health
Primary listing
NYSE
Employees
24,535
Headquarters
Weybridge, United Kingdom
Website
www.haleon.com

Haleon Metrics

BasicAdvanced
$41B
38.46
$0.24
0.25
$0.18
2.69%

What the Analysts think about Haleon

Analyst ratings (Buy, Hold, Sell) for Haleon stock.
Analyst projections of the future price of Haleon stock.

Bulls say / Bears say

Haleon delivered sequential momentum, with Q2 2026 organic revenue growth accelerating to 3.1% from 2.2% in Q1, and management maintained full-year guidance of 3%–5% organic growth plus high-single-digit adjusted operating-profit growth. (Haleon)
Oral Health is a clear growth engine: H1 organic revenue increased 7.3%, led by Sensodyne and parodontax innovation, while 73% of the portfolio gained or maintained market share. (Haleon)
Operating leverage is improving: H1 adjusted gross margin expanded 140 basis points, adjusted operating profit grew 8.2%, free cash flow reached £769 million, and Haleon completed £457 million of a planned £500 million 2026 buyback while raising its interim dividend 9%. (Haleon)
Haleon’s Respiratory Health revenue declined 4.7% organically in H1 2026, while Europe was flat and weakened in Q2, highlighting sensitivity to a weak cold-and-flu season and soft regional demand. (Haleon)
U.S. retail execution is requiring more promotional support: over 21% of second-quarter U.S. sales were sold on promotion, and Haleon offered retailers lower prices and improved commercial terms to secure shelf space. This could pressure realized pricing and margins if value-conscious consumers remain cautious. (Reuters)
Reported H1 operating profit fell 2.6% and diluted EPS declined 4.5%, partly reflecting restructuring costs; net debt remained 2.5x adjusted EBITDA. This leaves Haleon exposed to execution risk as it funds restructuring, growth investment, manufacturing expansion, buybacks and dividends simultaneously. (Haleon)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.

Haleon Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Haleon Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Haleon News

AllArticlesVideos

Haleon secures better shelf space at Walmart, Target in bid to boost market share

Reuters2 weeks ago

Jefferies raises Haleon price target to 410p on margin strength

Proactive Investors3 weeks ago

Haleon slides as quality of growth questioned

Proactive Investors2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.